Xian Mo, Feng Mulin, Dong Yan, Wei Nili, Su Qiujuan, Li Jing
Department of Allergy and Clinical Immunology, State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Guangzhou First People's Hospital of Guangdong Province, Guangzhou, China.
Int Arch Allergy Immunol. 2020;181(1):71-80. doi: 10.1159/000503143. Epub 2019 Nov 13.
Few studies have directly compared the immunologic responses to specific subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT).
We aimed to directly compare clinical efficacy and immunological responses between SLIT and SCIT in allergic rhinitis (AR) sensitized to house dust mites.
Sixty-seven patients (age 5-55 years) with moderate-severe Dermatophagoides pteronyssinus (Der-p) and Dermatophagoides farinae AR with or without asthma were randomized (2:2:1) into SLIT (n = 27), SCIT (n = 26) and placebo (n = 14) groups. Symptom and medication scores, visual analogue score, serum Der-p specific immunoglobulin G4 (Der-p-sIgG4), CD4+CD25+FoxP3+ regulatory T cells (Tregs) and serum cytokines were measured.
After 1-year treatment, a significant improvement of total rhinitis score (TRS), total rhinitis medication score (TRMS) and visual analogue score occurred in both SLIT and SCIT. There were no differences in clinical efficacy except for TRMS (p = 0.026) when SLIT and SCIT were directly compared. CD4+CD25+FoxP3+ Tregs had a trend towards upregulation in the 2 modes and inversely correlated with TRS (p = 0.024) only in SLIT. Der-p-sIgG4 significantly increased in SLIT and SCIT (p < 0.05), and it was 30 times higher in SCIT than SLIT after the treatment (p < 0.05). Serum interferon-γ significantly increased only in SCIT after 1 (p = 0.008), 6 (p = 0.007) and 12 (p = 0.008) months of treatment and inversely correlated with TRS (p = 0.032).
While SCIT and SLIT have similar rates of clinical improvement, the 2 modes reveal heterogeneous changes of CD4+CD25+Foxp3+ Tregs, sIgG4 and cytokines.
很少有研究直接比较特异性皮下免疫疗法(SCIT)和舌下免疫疗法(SLIT)的免疫反应。
我们旨在直接比较屋尘螨致敏性变应性鼻炎(AR)患者中SLIT和SCIT的临床疗效及免疫反应。
67例年龄在5至55岁之间、患有中重度柏氏嗜皮螨(Der-p)和粉尘螨变应性鼻炎且有或无哮喘的患者被随机(2:2:1)分为SLIT组(n = 27)、SCIT组(n = 26)和安慰剂组(n = 14)。测量症状和用药评分、视觉模拟评分、血清Der-p特异性免疫球蛋白G4(Der-p-sIgG4)、CD4+CD25+FoxP3+调节性T细胞(Tregs)和血清细胞因子。
经过1年治疗,SLIT组和SCIT组的总鼻炎评分(TRS)、总鼻炎用药评分(TRMS)和视觉模拟评分均有显著改善。直接比较SLIT组和SCIT组时,除TRMS外(p = 0.026),临床疗效无差异。两种治疗方式中CD4+CD25+FoxP3+ Tregs均有上调趋势,且仅在SLIT组中与TRS呈负相关(p = 0.024)。SLIT组和SCIT组中Der-p-sIgG4均显著升高(p < 0.05),治疗后SCIT组中该指标比SLIT组高30倍(p < 0.05)。治疗1个月(p = 0.008)、6个月(p = 0.007)和12个月(p = 0.008)后,仅SCIT组血清干扰素-γ显著升高,且与TRS呈负相关(p = 0.032)。
虽然SCIT和SLIT的临床改善率相似,但两种治疗方式中CD4+CD25+Foxp3+ Tregs、sIgG4和细胞因子的变化存在差异。